In last trading session, Akero Therapeutics Inc (NASDAQ:AKRO) saw 1.42 million shares changing hands with its beta currently measuring -0.26. Company’s recent per share price level of $39.96 trading at $2.08 or 5.49% at ring of the bell on the day assigns it a market valuation of $3.19B. That closing price of AKRO’s stock is at a discount of -46.15% from its 52-week high price of $58.40 and is indicating a premium of 55.31% from its 52-week low price of $17.86.
For Akero Therapeutics Inc (AKRO), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 4 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Akero Therapeutics Inc (NASDAQ:AKRO) trade information
Upright in the green during last session for gaining 5.49%, in the last five days AKRO remained trading in the red while hitting it’s week-highest on Friday, 05/09/25 when the stock touched $39.96 price level, adding 10.82% to its value on the day. Akero Therapeutics Inc’s shares saw a change of 43.64% in year-to-date performance and have moved -5.73% in past 5-day. Akero Therapeutics Inc (NASDAQ:AKRO) showed a performance of 4.94% in past 30-days.
Wall Street analysts have assigned a consensus price target of 45 to the stock, which implies a rise of 11.2% to its current value. Analysts have been projecting 38 as a low price target for the stock while placing it at a high target of 56. It follows that stock’s current price would jump 4.9% in reaching the projected high whereas dropping to the targeted low would mean a gain of 4.9% for stock’s current value.
Akero Therapeutics Inc (AKRO) estimates and forecasts
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -5.28% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -3.79% while estimates for its earnings growth in next 5 years are of -8.83%.
Akero Therapeutics Inc (NASDAQ:AKRO)’s Major holders
JANUS HENDERSON GROUP PLC is the top institutional holder at AKRO for having 6.88 million shares of worth $161.28 million. And as of 2024-06-30, it was holding 9.9425 of the company’s outstanding shares.
The second largest institutional holder is BLACKROCK INC., which was holding about 5.59 million shares on 2024-06-30. The number of shares represents firm’s hold over 8.0778 of outstanding shares, having a total worth of $131.06 million.
On the other hand, VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund and iShares Trust-iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Jan 31, 2025, the former fund manager was holding 4.07 shares of worth $162.63 million or 5.11% of the total outstanding shares. The later fund manager was in possession of 1.96 shares on Mar 31, 2025, making its stake of worth around $78.41 million in the company or a holder of 2.46% of company’s stock.
